Data gathered: November 27
Alternative Data for Akebia Therapeutics
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | 11 | Sign up | Sign up | Sign up |
| Sentiment | 70 | Sign up | Sign up | Sign up |
| Webpage traffic | 8,000 | Sign up | Sign up | Sign up |
| Employee Rating | 68 | Sign up | Sign up | Sign up |
| Google Trends | 16 | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Facebook Engagement | N/A | Sign up | Sign up | Sign up |
| Facebook Followers | 181 | Sign up | Sign up | Sign up |
| Instagram Followers | 412 | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 83 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 20,014 | Sign up | Sign up | Sign up |
| Twitter Followers | 2,102 | Sign up | Sign up | Sign up |
| Twitter Mentions | 27 | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| Business Outlook | 49 | Sign up | Sign up | Sign up |
| Linkedin Employees | 249 | Sign up | Sign up | Sign up |
About Akebia Therapeutics
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases.
| Price | $2.06 |
| Target Price | Sign up |
| Volume | 1,290,000 |
| Market Cap | $421M |
| Year Range | $0.86 - $2.24 |
| Dividend Yield | 0% |
| Analyst Rating | 100% buy |
| Industry | Biotechnology |
In the news
 |
Akebia Therapeutics to Present at the 36th Annual Piper Sandler Healthcare ConferenceNovember 25 - Investing.com |
 |
Akebia Therapeutics (NASDAQ:AKBA) Downgraded by StockNews.com to SellNovember 24 - ETF Daily News |
 |
Q3 2024 Earnings: Hold Akebia TherapeuticsNovember 19 - SeekingAlpha |
 |
Akebia Therapeutics to Present at the Jefferies London Healthcare ConferenceNovember 11 - Yahoo |
Akebia Therapeutics, Inc. (NASDAQ:AKBA) Released Earnings Last Week And Analysts Lifted Their Price Target To US$5.50November 8 - Yahoo |
|
 |
Akebia Therapeutics Inc (AKBA) Q3 2024 Earnings Call Highlights: Navigating Revenue Challenges ...November 7 - Yahoo |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q3 '24 | 37M | 14M | 23M | -20M | -3.5M | 0.000 |
| Q2 '24 | 44M | 17M | 27M | -8.6M | 280,000 | -0.040 |
| Q1 '24 | 32M | 12M | 20M | -18M | -5.9M | -0.090 |
| Q4 '23 | 56M | 19M | 38M | 610,000 | 10M | 0.003 |
| Q3 '23 | 42M | 18M | 24M | -14M | -4M | -0.080 |
Insider Transactions View All
| Dahan Michel filed to sell 672,092 shares at $1.3. May 14 '24 |
| Hadas Nicole R. filed to sell 651,243 shares at $1.3. May 14 '24 |
| Burke Steven Keith filed to sell 695,840 shares at $1.6. March 1 '24 |
| Hadas Nicole R. filed to sell 663,259 shares at $1.6. March 1 '24 |
| Dahan Michel filed to sell 706,932 shares at $1.6. March 1 '24 |
Similar companies
Read more about Akebia Therapeutics (AKBA) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, google trends, 4chan mentions, facebook engagement, facebook followers, instagram followers, reddit mentions, stocktwits mentions, stocktwits subscribers, twitter followers, twitter mentions, news mentions, customer reviews, business outlook & linkedin employees.
What is the Market Cap of Akebia Therapeutics?
The Market Cap of Akebia Therapeutics is $421M.
What is the current stock price of Akebia Therapeutics?
Currently, the price of one share of Akebia Therapeutics stock is $2.06.
How can I analyze the AKBA stock price chart for investment decisions?
The AKBA stock price chart above provides a comprehensive visual representation of Akebia Therapeutics' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Akebia Therapeutics shares. Our platform offers an up-to-date AKBA stock price chart, along with technical data analysis and alternative data insights.
Does AKBA offer dividends to its shareholders?
As of our latest update, Akebia Therapeutics (AKBA) does not offer dividends to its shareholders. Investors interested in Akebia Therapeutics should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
What are some of the similar stocks of Akebia Therapeutics?
Some of the similar stocks of Akebia Therapeutics are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
.